HZHao Zheng

Hao Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hao Zheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of dual-energy computed tomography combined with radiomics in the clinical diagnosis of lung cancer: a systematic review and meta-analysis

    by Jiaye Zhang, Jie Lin, Junna Wang, Yuanyu Liang, Chen Gao, Hao Zheng

    Background: Lung cancer is the leading cause of cancer-related mortality globally, with early precise diagnosis critical for improving prognosis. Conventional computed tomography (CT) lacks sufficient sensitivity for early malignant nodule detection, while pathological biopsy is invasive and limited by sampling bias—creating an urgent need for non-invasive, high-accuracy diagnostic tools. This study aimed to systematically evaluate the diagnostic efficacy of dual-energy computed tomography (DECT) across different clinical scenarios of lung cancer and further explore the additional diagnostic value of its integration with radiomics models, aiming to provide an evidence-based reference for precise imaging assessment and clinical decision-making in lung cancer. Methods: We systematically searched relevant databases, screened eligible studies, applied quality assessment tools for comprehensive bias evaluation, and analyzed their diagnostic accuracy. Statistical analysis software was used to perform heterogeneity test and subgroup analysis and sensitivity analysis, while Spearman rank correlation test was employed to examine the threshold effect. Results: A total of 2,899 lesions were included across the 21 studies [2016–2025]. Differentiating benign from malignant: DECT achieved a pooled sensitivity of 0.87 [95% confidence interval (CI): 0.83–0.91], a specificity of 0.88 (95% CI: 0.79–0.93), and an area under the curve (AUC) of 0.93 (95% CI: 0.90–0.95). Integrated DECT-radiomics model showed training set a sensitivity of 0.90, a specificity of 0.88, an AUC of 0.94 (95% CIs: 0.85–0.93, 0.80–0.94, 0.85–1.00). Invasiveness prediction: DECT demonstrated a sensitivity of 0.83 (0.80–0.85), a specificity of 0.79 (0.76–0.83), and an AUC of 0.85 (0.81–0.88). DECT-radiomics integration improved performance, with training set a sensitivity of 0.84, a specificity of 0.84, and an AUC of 0.91 (95% CIs: 0.80–0.87, 0.79–0.87, 0.88–0.93). In addition, the diagnostic efficacy of DECT for predicting lymph node metastasis (LNM) was evaluated independently: a sensitivity of 0.84 (0.75–0.90), a specificity of 0.83 (0.75–0.89), an AUC of 0.90 (0.87–0.93). Subgroup regression analysis indicated that feature extraction methods and radiomics algorithms are the most important sources of heterogeneity. This study did not find significant threshold effect or publication bias (P>0.05). Conclusions: DECT demonstrates high diagnostic accuracy in assessing key characteristics of lung cancer. When integrated with radiomics, it significantly improves the performance of distinguishing benign from malignant lesions and enhances the accuracy of invasiveness prediction, thereby offering robust technical support for optimizing precision imaging assessment strategies in lung cancer. In future research, the clinical generalizability and translational potential of this combined technique could be further validated through an expanded sample size and the inclusion of lung cancer cases representing diverse pathological subtypes.


  • Open Access

    Peritumoral Radiomic Features on CT for Differential Diagnosis in Small-Cell Lung Cancer: Potential for Surgical Decision-Making

    by Jie Lin, Hao Zheng, Yuan Dong, Lanqi Fu, Yujie Ding, Shucheng Huang, Shiwei Wang, Junna Wang

    Introduction: Small-cell lung cancer (SCLC) is a leading cause of cancer-related mortality worldwide, with limited therapeutic outcomes and poor prognosis. Accurate diagnosis and optimal surgical decision-making remain critical challenges. This study aimed to develop and validate a clinical-radiomics nomogram integrating computed tomography (CT) radiomic features of the peritumoral region and clinical factors to improve SCLC diagnosis and guide surgical planning. Methods: A retrospective cohort of 113 patients (54 SCLC, 59 non-small cell lung cancer) was analyzed. CT images were processed to extract 1050 radiomic features from both intratumoral and peritumoral (2-mm expanded) ROIs. Feature selection was performed using t-tests, LASSO regression, and mRMR analysis. Logistic regression models were constructed for original and expanded ROIs, and a clinical-radiomics nomogram was developed by combining significant radiomic features with independent clinical predictors (gender, smoking history, tumor diameter, glitch, and neuron-specific enolase levels). Model performance was evaluated using ROC curves, AUC, sensitivity, specificity, and CIC curves. Results: The expanded ROI radiomics model outperformed the original ROI and clinical models, achieving higher accuracy (0.83 vs 0.76/0.70), sensitivity (0.80 vs 0.74/0.77), specificity (0.85 vs 0.75/0.65), and AUC (0.85 vs 0.76/0.71). The clinical-radiomics nomogram demonstrated superior diagnostic performance, with an AUC of 0.96 (95% CI: 0.88-1.00), accuracy of 0.91, sensitivity of 0.92, and specificity of 0.90. CIC analysis confirmed its clinical utility for surgical decision-making at intermediate-risk thresholds. Conclusion: The integration of peritumoral radiomic features and clinical factors into a nomogram provides a non-invasive tool for SCLC diagnosis and surgical planning. The superiority of the expanded model substantiates the potential presence of SCLC in peri-tumoral tissues that may be imperceptible through conventional imaging, thereby offering guidance for surgical decision-making. This approach has potential for improving treatment outcomes and warrants further validation in multicenter studies.